Compare ABRDN Physical Gold Shares ETF (SGOL) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Stryker Corporation — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.97 (market cap $7.03B), while Stryker Corporation trades at $277.48 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 15.1× ABRDN Physical Gold Shares ETF's market cap, and Stryker Corporation pays a 1.27% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Stryker Corporation for 21 Days on average.
| SGOL | SYK | |
|---|---|---|
Market Cap | $7.03B | $106.24B |
Volume | 2,350,550 | 2,982,001 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $388.35 |
52-Week Low | $37.54 | $269.75 |
Typical Hold Time | 57 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.94, up 2.36% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent softer inflation data provided some support. Moving averages indicate strong bearish momentum while oscillators remain neutral, suggesting potential consolidation near current levels.
The outlook remains cautious with technical indicators favoring downside momentum, though oversold conditions could provide near-term support. Key risks include persistent inflation concerns and Fed policy uncertainty, while potential catalysts include geopolitical tensions and sustained gold demand from China. Investors should monitor Treasury yield movements and inflation data for directional cues.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
